LOGIN  |  REGISTER
Amneal Pharmaceuticals

TruBridge Announces Second Quarter 2025 Conference Call to Be Held Friday, August 8, 2025

August 01, 2025 | Last Trade: US$19.71 0.32 1.65

MOBILE, Ala. / Aug 01, 2025 / Business Wire / TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced that it will release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, after the market closes. The Company will host a conference call at 7:30 a.m. Central Time, 8:30 a.m. Eastern Time on Friday, August 8, 2025. To access this interactive teleconference, dial (877) 407-0890 and request connection to the TruBridge earnings conference call.

A live broadcast of TruBridge’s conference call will also be available online at the Company’s investor relations website, investors.trubridge.com. The 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About TruBridge

TruBridge proudly supports rural and community hospitals and providers in their efforts to stay strong, independent, and deeply rooted in the communities they serve. Backed by more than 45 years of healthcare experience and trusted by over 1,500 clients nationwide, we offer a mix of technology, services, and strategic expertise — including revenue cycle management, electronic health records (EHR) and analytics — all designed singularly for the realities of rural and community healthcare. With a steadfast commitment to keeping care local, TruBridge helps hospitals flourish as the economic heart of their communities, delivering high-quality, personal care close to home. For more information, visit www.trubridge.com.

C4 Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page